Copyright
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Uridine diphosphate glucuronosyltransferase 1A1 prevents the progression of liver injury
Jin-Lian Jiang, Yi-Yang Zhou, Wei-Wei Zhong, Lin-Yan Luo, Si-Ying Liu, Xiao-Yu Xie, Mao-Yuan Mu, Zhi-Gang Jiang, Yuan Xue, Jian Zhang, Yi-Huai He
Jin-Lian Jiang, Yi-Yang Zhou, Si-Ying Liu, Yi-Huai He, Department of Infectious Diseases, Affiliated Hospital of Zunyi Medical University, Zunyi 563000, Guizhou Province, China
Wei-Wei Zhong, Department of Infectious Diseases, Jingmen Central Hospital, Jingmen 448000, Hubei Province, China
Lin-Yan Luo, Department of Respiratory Medicine, Anshun People’s Hospital, Anshun 561099, Guizhou Province, China
Xiao-Yu Xie, Department of General Practice, Affiliated Hospital of Zunyi Medical University, Zunyi 563000, Guizhou Province, China
Mao-Yuan Mu, Department of Intervention Radiology, Affiliated Hospital of Zunyi Medical University, Zunyi 563000, Guizhou Province, China
Zhi-Gang Jiang, School of Public Health, Zunyi Medical University, Zunyi 563099, Guizhou Province, China
Yuan Xue, Department of Liver Diseases, Third People’s Hospital of Changzhou, Changzhou 213000, Jiangsu Province, China
Jian Zhang, Department of Digestion, Dafang County People’s Hospital, Bijie 551600, Guizhou Province, China
Co-first authors: Jin-Lian Jiang and Yi-Yang Zhou.
Author contributions: Jiang JL and Zhou YY contributed equally to this work; Jiang JL, Zhou YY, and He YH conceived and designed the research; Jiang JL, Zhou YY, Zhong WW, Luo LY, Liu SY, and Xie XY collected data and conducted research; Jiang JL, Zhou YY, Mu MY, Jiang ZG, Xue Y, and Zhang J analyzed and interpreted data; Jiang JL and Zhou YY wrote the initial draft; He YH revised the manuscript; and all authors read and approved the final version of the manuscript.
Supported by the Science and Technology Research Foundations of Guizhou Province, No. QKHJC-ZK(2022)YB642; Zunyi Science and Technology Plan Project, No. ZSKHHZ(2022)344, No. ZSKHHZ(2022)360, and No. ZYK160; Hubei Province Central Leading Local Science and Technology Development Special Project, No. 2022BCE030; Changzhou Science and Technology Projects, No. CE20225054; and Bijie City Science and Planning Bureau, No. BKH(2022)8.
Institutional review board statement: The study was reviewed and approved by the Zunyi Medical University Medical Ethics Review Committee [Approval No. ZYFYLS (2018)28 and No. ZYLS(2022)1-059].
Institutional animal care and use committee statement: All procedures involving animals were reviewed and approved by the Affidavit of Approval of Animal Welfare and Ethical of Zunyi Medical University (Approval No. ZMU21-2107-003 and No. ZMU11-2203-314).
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Data sharing statement: The datasets generated and analyzed during the current study are available from the corresponding author on reasonable request.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
https://creativecommons.org/Licenses/by-nc/4.0/ Corresponding author: Yi-Huai He, MD, Director, Department of Infectious Diseases, Affiliated Hospital of Zunyi Medical University, No. 149 Dalian Road, Zunyi 563000, Guizhou Province, China.
993565989@qq.com
Received: September 28, 2023
Peer-review started: September 28, 2023
First decision: December 6, 2023
Revised: January 2, 2024
Accepted: January 29, 2024
Article in press: January 29, 2024
Published online: March 7, 2024
Processing time: 159 Days and 20 Hours
BACKGROUND
Uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) plays a crucial role in metabolizing and detoxifying endogenous and exogenous substances. However, its contribution to the progression of liver damage remains unclear.
AIM
To determine the role and mechanism of UGT1A1 in liver damage progression.
METHODS
We investigated the relationship between UGT1A1 expression and liver injury through clinical research. Additionally, the impact and mechanism of UGT1A1 on the progression of liver injury was analyzed through a mouse model study.
RESULTS
Patients with UGT1A1 gene mutations showed varying degrees of liver damage, while patients with acute-on-chronic liver failure (ACLF) exhibited relatively reduced levels of UGT1A1 protein in the liver as compared to patients with chronic hepatitis. This suggests that low UGT1A1 levels may be associated with the progression of liver damage. In mouse models of liver injury induced by carbon tetrachloride (CCl4) and concanavalin A (ConA), the hepatic levels of UGT1A1 protein were found to be increased. In mice with lipopolysaccharide or liver steatosis-mediated liver-injury progression, the hepatic protein levels of UGT1A1 were decreased, which is consistent with the observations in patients with ACLF. UGT1A1 knockout exacerbated CCl4- and ConA-induced liver injury, hepatocyte apoptosis and necroptosis in mice, intensified hepatocyte endoplasmic reticulum (ER) stress and oxidative stress, and disrupted lipid metabolism.
CONCLUSION
UGT1A1 is upregulated as a compensatory response during liver injury, and interference with this upregulation process may worsen liver injury. UGT1A1 reduces ER stress, oxidative stress, and lipid metabolism disorder, thereby mitigating hepatocyte apoptosis and necroptosis.
Core Tip: The role and mechanism of hepatic uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) in the progression of liver injury are still not fully understood. This study found that inhibiting compensatory upregulation of UGT1A1 promotes the progression of liver injury. The mechanism may be related to low levels of UGT1A1 exacerbating endoplasmic reticulum stress and oxidative stress, and disrupting lipid metabolism, thereby exacerbating hepatocyte apoptosis and necroptosis.
